ArticleCancer cell2021

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Yujue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.